Human Microbiome Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028, Segmented By, Product (Prebiotics, Probiotics, Medical Food, Supplements, Others), By Application (Therapeutic, Diagnostic), By Disease (Infectious Disease, Endocrine and Metabolic Disorders, Gastrointestinal Diseases, Cancer, and Other Disease), By Technology (Genomics, Proteomics, Metabolomics), By Type (FMT, Peptide, Live Biotherapeutic Product and Others), By Region and Competition

Global human microbiome market is anticipated to observe an impressive growth during the forecast period, 2024-2028. The market growth can be attributed to ongoing increasing demand for the development of human microbiome therapy. The human microbiome therapy is actively associated with the drug development procedures, the surge in demand for advanced medicines is driving the growth of the global human microbiome therapy market in the forecast period. Moreover, increasing instances of lifestyle diseases is driving the market growth in the upcoming future.

Increased Application in Cancer Treatment

The gut microbiota has found a link between cancer and is now utilized to improve or boost the efficiency of anticancer drugs. Altered microbiota has been found as the major cause for developing the resistance to chemo medicines and various immune checkpoint inhibitors, whereas taking supplementary with other bacterial species restores the anticancer treatment responses. For instance, the increasing colorectal cancer (CRC), the development of cancer from the colon is associated with some specific type of bacteria. According to Clinicaltrials.gov, 5213 clinical trials are in different phases of development across the globe for Colorectal Cancer. Thus, increasing the research and development to create a better understanding of human microbiota’s interactions with cancer can help the researchers to lead to the development of new cancer prevention strategies, aid patients with more effective and improved treatment, and thereby reduce treatment complications in the cancer treatment, which in turn is anticipated to boost the human microbiome market. According to Clinicaltrials.gov, 5213 clinical trials are in different phases of development across the globe for Colorectal Cancer. Prebiotics are anticipated to hold the largest market share in the next five years and dominate the market. The market domination is expected on the backbone of rising general awareness among the population towards health and lifestyle. Moreover, as microbiota has a strong relation due its gut colonization and has a significant role in the physiological processes such as vitamin synthesis, nutrient uptake, immune system development and therefore any diversity in microbiota has been linked to a variety of diseases including cancer. Some of the gut microbiota have a colonial association with few bacteria which result in lowered risk of certain cancers . Therefore, identifying certain microbiota resulting in the preventing the onset of tumors or control their infection and thus promoting the human microbiome demand and is further expected to anticipate the increase in human microbiome market demand.

Growing Human Awareness for Better health

Autoimmune diseases such as diabetes, rheumatoid, arthritis, muscular dystrophy, multiple sclerosis, and fibromyalgia are associated with dysfunction in the microbiome. Since the bacteria in the microbiome helps digest our food, protect against other disease-causing bacteria, regulate our immune system, produce vitamin B12, thiamine, riboflavin, and Vitamin K essential for blood coagulation. Moreover, the response to the intake of probiotics and prebiotics observed among the healthy adults supports the existence of potential gut microbiota thus increasing the acceptability for human microbiota among the population and thereby supporting the market. Increasing Also, growing awareness regarding the relation of nutrition, diet, and health is expected to support the market growth in the coming future. Furthermore rising awareness about the human microbiome is creating a huge opportunity for the patient suffering Gastrointestinal (GI) illness such as Gut dysbiosis and is therefore creating treatment opportunities such as fecal transplants ,etc. The fecal transplant includes the transfer healthy gut microbiota from an individual to the gastrointestinal tract of a patient suffering gut dysbiosis. Therefore targeting gut microbiota with frequent clinical interventions has now been as a novel approach for disease treatments and is thus human microbiome is in in huge demand expected to treat and even reverse illness including gut health.

Growing Focus on Human Microbiome Therapeutics Development

The potential of medicinal drugs can be highly influenced by the microbiome of the human gut and this connectivity between the bacteria and specific diseases has the possibility of creating new drugs and vaccines. Multiple studies have illustrated that a balance in the human gut microbiome is necessary and creating this helps in treatment of various ailments. Since, the microbes are organism rich in enzymes and thus can be utilized to produce various types of therapeutic application. The Microbiome therapy has become popular in the recent years for the treatment of various diseases, with the rising development of microbiome therapeutic drugs and therapies, thus creating a huge demand for human microbiome market in future. The National Center for Complementary and Integrative Health (NCCIH) is among the many agencies funding research on the microbiome. Additionally, the National Institutes of Health (NIH) has spent USD 215 million on the Human Microbiome Project (HMP) along with the USD 728 million spent on extramural human microbiome research initiatives outside of HMP over a ten-year period, thereby creating more opportunities for the human microbiome market and thus driving the market in the future.

Growing Incidence of Lifestyle Diseases

The gut microbiota is largely affected by the type of diet we are exposing it to, mostly by the dietary fats and proteins. According to WHO, non-communicable diseases or NCDs, of which lifestyle diseases are a part, is over 70% of all deaths across the globe. Incidence of non-communicable disease such as inflammatory bowel disease, inflammatory chronic disease and allergies has become an important health issue worldwide. Lifestyle diseases are mostly due to three lifestyle behaviors -smoking, unhealthy diet and physical inactivity resulting in development of severe chronic diseases, such as heart diseases, stroke, diabetes, obesity, Constructive obstructive pulmonary disease, and distinct type of cancers, etc. To maintain homeostasis and preserve health a good balance and healthy function for bacteria groups i.e., a healthy gut microbiome in the colon is necessary. People are more aware about their lifestyle ad food choices and is therefore taking high precautions and taking their focus to intake the required healthy bacteria from the outside sources easily available to the consumers worldwide. For instance, Yakult 50 Billion Light – a Lactobacillus casei bacteria rich (Shirota), high value added fermented drink, rich in dietary fibers, nutrients such as Vitamin D, A and Vitamin E.

 The changing dietary habits worldwide i.e., consumption of more processed and unhealthy foods, unhealthy lifestyle habits such as smoking, alcohol, drug consumption leads to gut dysbiosis and other inflammatory gut health issues, which in turn is creating more demand for the human microbiome market and thereby is anticipated to support the market in the future.

Download Free Sample Report

Market Segmentation

The Global Human Microbiome Market is segmented by product, application, diseases, technology, Type, competitional landscape, and regional distribution. Based on product, the market is further segmented into prebiotics, probiotics, medical food, supplements, and others. Based on the application, the market is further fragmented into therapeutic and diagnostic. Depending on the Disease, the market is segmented into Infectious Disease, Endocrine and Metabolic Disorders, Gastrointestinal Diseases, Cancer, and Other Disease. Based on the Technology, the market is further grouped into Genomics, Proteomics and Metabolomics. Depending on the Type, the market is grouped into FMT, Peptide, Live Biotherapeutic Product and Others.

Recent Developments

In 2018, Rebiotrix joined with Ferring pharmaceuticals-a globally recognized specialty pharmaceutical company to lead their ability to make microbiota-based live biotherapeutics more efficiently and supply worldwide.

In November 2022, Ferring pharmaceuticals announced its product REBYOTA- a first class microbiota -based live biotherapeutic for the prevention of recurrence of Clostridioides difficile infection (CDI) among the individuals for 18 and above age . The REBYOTA safety is considered a largest clinical trial program in the field of microbiome-based therapeutics,and is now a US Food and FDA approved microbiota based live biotherapeutic.

Market Players

Enterome Bioscience SA, Yakult Honsha Co. Ltd., Dupont Inc., Seres Therapeutics Inc., Synthetic Biologics Inc., Second Genome Inc., uBiome Inc., Rebiotix Inc., Microbiome Therapeutics LLC, Osel Inc., Merck and Co., Inc., AOBiome LLC, Vithera Pharmaceuticals Inc., AG Metabiomics Corporation, Ferring Pharmaceuticals SA, are some of the key players operating in the Global Human Microbiome Market.

Report Scope:

In this report, global human microbiome market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Human Microbiome Market, By Product:
• Prebiotics
• Probiotics
• Medical Food
• Supplements
• Others
• Human Microbiome Market, By Application:
• Therapeutic
• Diagnostic
• Human Microbiome Market, By Disease:
• Infectious Disease
• Endocrine and Metabolic Disorders
• Gastrointestinal Diseases
• Cancer
• Other Diseases
• Human Microbiome Market, By Technology:
• Genomics
• Proteomics
• Metabolomics
• Human Microbiome Market, By Type:
• FMT
• Peptide
• Live Biotherapeutic Product
• Others
• Human Microbiome Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• South America
• Brazil
• Argentina
• Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global human microbiome market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Human Microbiome Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]